Intrexon | XON - Gross Profit On Sales


Intrexon reported $-297K in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Agenus USD 34.2M 4.61M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 6.48B 307M Sep/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Incyte USD 1.39B 118.68M Dec/2025
Intrexon USD -297K 167K Jun/2024
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
MacroGenics USD 31.11M 30.14M Dec/2025
MannKind USD 78.31M 76.21M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.25B 570M Dec/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Thermo Fisher Scientific USD 4.64B 419M Dec/2025
Veracyte USD 101.97M 10.69M Dec/2025
Xencor USD 21M 22.61M Sep/2025